Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is a promising biopharmaceutical company with a diverse pipeline of potential treatments for sight-threatening conditions, including diabetic macular edema, dry eye disease, and acute optic neuritis. FDA's recognition of ON as a significant unmet medical need and the potential for a $7 billion market in the US alone for ON highlights the high demand for new treatments. With a fully funded clinical program and promising results in phase 2 studies, Oculis Holding's OCS-05 has the potential to become a breakthrough neuroprotective treatment for a range of eye conditions, including MS relapse. The company's increased focus and investment into its precision medicine approach for DED and its accelerated market penetration for OCS-01 and OCS-05 support a positive outlook for the company's future success.

Bears say

Oculis Holding is approaching Phase 3 data readout for their lead asset OCS-01 in diabetic macular edema (DME), which has shown promising results in earlier studies, potentially expanding the $3 billion DME market. However, the company will face competition from other treatments and the potential side effects of OCS-01 may limit its adoption. Additionally, the company's plan to out-license commercialization efforts may impact their financials and hinder their ability to reach a wider market.

OCS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 7 analysts, OCS has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.